Status:
NOT_YET_RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia
Lead Sponsor:
Chong Kun Dang Pharmaceutical
Conditions:
Androgenetic Alopecia
Eligibility:
MALE
18-50 years
Phase:
PHASE3
Brief Summary
This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia
Detailed Description
The participants were randomly assigned to one of the following groups: CKD-843 dose #1, CKD-843 dose #2, placebo, or Dutasteride group. They received the assigned medication, placebo for blinding, or...
Eligibility Criteria
Inclusion
- Key
- Male of age 18-50 years
- Clinical Diagnosis of Androgenetic Alopecia
- Written informed consent
- Key
Exclusion
- Other types of Alopecia or other diseases that can cause hair loss
- Clinically significant scalp disease such as seborrheic dermatitis or psoriasis
- Clinically significant hepatic disease, thyroid disease, or mental illness, as determined by the Investigator
- Participants who do not agree to use contraception during the trial and for 24 weeks after the last dose, and plan to provide sperm or conceive within 24 weeks after the last dose
Key Trial Info
Start Date :
April 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 17 2027
Estimated Enrollment :
288 Patients enrolled
Trial Details
Trial ID
NCT06916793
Start Date
April 30 2025
End Date
September 17 2027
Last Update
April 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea